Business Wire

NTT DATA Unveils Global Insights on GenAI Adoption in Banking: Divergent Strategies for Boosting Productivity vs. Cutting Costs

10.2.2025 05:00:00 CET | Business Wire | Press release

Share

Research from NTT DATA finds that as GenAI adoption rises, new pressures on return of investment are at the forefront of the challenges facing the banking industry.

NTT DATA, a global digital business and IT services leader, has today launched a new global research report uncovering the use of generative AI (GenAI) in the banking sector worldwide. The report, titled “Intelligent banking in the Age of AI,” has found that despite the growing adoption of GenAI technology in the banking industry, banks and financial institutions are split when it comes to outcome-based strategies – only half of banks (50%) see it as a tool for improving productivity and efficiency. Similarly, half (49%) believe it can be used for reducing operational IT spend.

Transforming Banking Through GenAI

GenAI is more disruptive than any previous advance in banking technology. It is less a question of if, but when banks embrace this technology, due to its transformative ability to embed intelligence at every layer of the banking ecosystem, from core banking to front-end systems. GenAI is already making waves in the banking industry, with 6 in 10 organizations (58%) already fully embracing its transformative potential, an increase from 2023, when only 45% of organizations had fully embraced GenAI, according to NTT DATA’s research.

“Generative AI represents a pivotal moment for the banking industry,” said Robb Rasmussen, Head of Global Marketing & Communications, NTT DATA. “While the potential benefits are enormous, the challenges of implementing GenAI are complex and varied, requiring careful navigation and a structured approach. Given the anticipated high spending on GenAI, achieving a return on investment is crucial. Many banks will be expecting GenAI to drive long-term savings by automating IT tasks, improving operational efficiency, and creating competitive advantages, but it’s important to note that achieving meaningful ROI requires a clear strategy, tailored implementation, and robust governance at the same time.”

Financial constraints increasing pressure on ROI

ROI has become a top priority for GenAI implementations, yet banking organizations are split in their opinions of which strategies are most important to them. Banks have long struggled with boosting productivity, and GenAI is poised to present a solution to this problem, but only half of banking leaders (50%) see it as a solution to current productivity woes. Cost optimization is another area where banks are split, with just under half (49%) looking to reduce IT budgets accordingly.

This disparity is highlighted on a global scale too – for example, almost 6 in 10 US banks (59%) are keen to reduce IT budgets and almost half (47%) want to cut operations budgets, while only 4 in 10 banks in Europe (43%) have IT budgets front of mind and just over a third (36%) are concerned with operations costs. Meanwhile productivity is the most important factor for European banks (46%), yet the US and APAC are placing even more emphasis on productivity themselves in comparison.

Key performance indicators (KPIs) that financial institutions are using or planning to use to evaluate the success of Generative AI initiatives:

Europe

US

APAC

LATAM

Japan

Improved productivity/efficiency

46%

52%

58%

43%

35%

Competitive advantage

42%

48%

57%

48%

40%

Cutting costs/Reducing IT budget

43%

59%

51%

44%

48%

Cutting costs/ Reducing operations budget

36%

47%

49%

36%

28%

Accelerate speed to innovate

37%

34%

50%

41%

35%

Increased net promoter score

29%

25%

31%

26%

40%

Differing strategies across differing regions

Strategies for realizing these benefits of GenAI differ vastly among organizations too. While around half of organizations are focusing on collaboration between humans and AI (51%) or a hybrid approach with existing systems (47%), over a quarter (28%) of banks are hoping to fully automate tasks and remove the need for manual input entirely. Fully automating tasks is an area which divides opinions worldwide as well, with a quarter of banks in the UK (25%) and Europe (24%) looking to fully automate the process, while almost a third of banks (32%) in the Americas and 35% of Japanese banks are looking to do the same.

Robb Rasmussen, Head of Global Marketing & Communications, NTT DATA added: “It is clear that the ability to balance innovation with fiscal responsibility will define success for banks. However, many banks are lacking in maturity when it comes to this technology and are unsure where to start. Partnering with systems integrators can be a good starting point, allowing them to access the latest knowledge while ensuring compliance with industry regulations. By working with specialized providers, banks can ensure that GenAI implementations can deliver the desired ROI, while maintaining robust data protection measures and meeting both internal security standards and regulatory requirements.”

NTT DATA’s research dives into specific areas of the banking industry, including Payments and Wealth Management, as well as Fraud Prevention. To read the full report, please go to “Intelligent banking in the Age of AI”

About the Research

NTT DATA's survey was carried out on 810 banking leaders, from all global banking markets, and provides a 360-degree perspective on the sector's journey towards innovation and GenAI adoption. This survey was led by NTT DATA Group's Global Industry Office, part of the Global Marketing & Communications Headquarters.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250209166436/en/

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Align Partners Issues Public Shareholder Letter and Submits Formal Shareholder Proposals to DB Insurance9.2.2026 15:26:00 CET | Press release

Align Partners underscores DBI’s persistent undervaluation (0.40x Adjusted PBR), despite industry-leading profitability, identifying inefficient capital allocation and governance issues as primary driversAlign Partners outlines measures for capital efficiency and governance normalization; requests a revised “Value-up” plan and a formal response from the Board by March 6, 2026The proposals nominate two Independent Directors via separate election and calls for the reinstatement of the Internal Transaction Committee Align Partners Capital Management Inc. (“Align Partners”), a shareholder of DB Insurance Co., Ltd. (KRX:005830) (“DBI” or the “Company”) holding 1.9%, has issued a public shareholder letter to DBI’s Board of Directors aimed at strengthening capital allocation policy and governance oversight, and submitted formal shareholder proposals for the 2026 Annual General Meeting (“AGM”). Despite DBI’s robust fundamentals—including a 16.1% ROE and a 226% K-ICS ratio—the Company trades at

Promega Unveils Cellular Target Engagement Technology Aimed at Expanding the Druggable Proteome at SLAS 20269.2.2026 13:00:00 CET | Press release

TarSeer™ BRETSA™ Target Engagement System enables studies for difficult proteins early in drug discovery Promega Corporation is launching a new live-cell target engagement platform that could close a long-standing gap between biochemical and cellular assays for understudied or difficult-to-interrogate proteins. The TarSeer™ BRETSA™ Target Engagement System is a novel bioluminescence resonance energy transfer-based shift assay for detecting ligand-protein interactions in intact cells using protein denaturation. It gives drug discovery researchers early, target-specific cellular insights by validating weak or early chemical matter and expanding the targets accessible in live-cell drug discovery workflows. The technology will be debuted at the Society for Laboratory Automation and Screening (SLAS) International Conference and Exhibition in Boston, February 7-11, 2026. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260206015371/

Eurofins Viracor BioPharma Expands Bioanalytical Capabilities9.2.2026 13:00:00 CET | Press release

Eurofins Viracor BioPharma Services, a long‑standing and trusted partner for clinical trial testing solutions with deep expertise in specialty biomarkers and molecular assays, announces a significant expansion of its service portfolio with the addition of enhanced bioanalytical testing capabilities. These new services are fully aligned with Good Laboratory Practices (GLP) and Good Clinical Practices (GCP), enabling the company to enhance support of biopharmaceutical development programs with greater scientific breadth throughout the drug development workflow. This strategic advancement follows the successful relocation and integration of Eurofins Pharma Bioanalytics Services from St. Charles, Missouri, into Eurofins Viracor BioPharma’s purpose‑built, eleven‑acre facility in Lenexa, Kansas. The bioanalytical organization brings more than two decades of specialized experience in pharmacokinetics, immunogenicity, and biomarker testing. By combining both laboratories’ strengths, Eurofins V

HKTDC to Host World’s Largest One-Stop Jewellery Marketplace9.2.2026 11:37:00 CET | Press release

New Hard Pure Gold Pavilion showcases breakthrough gold technologies Organised by the Hong Kong Trade Development Council (HKTDC), the world’s largest one‑stop jewellery marketplace will return in early March under its proven “Two Shows, Two Venues” format. The 12th Hong Kong International Diamond, Gem & Pearl Show will take place from 2 to 6 March at AsiaWorld‑Expo, featuring a wide range of jewellery raw materials. Also, the 42nd Hong Kong International Jewellery Show will be held from 4 to 8 March at the Hong Kong Convention and Exhibition Centre, showcasing finished jewellery pieces. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260207153040/en/ Hong Kong International Jewellery Show and Hong Kong International Diamond, Gem & Pearl Show Jenny Koo, Deputy Executive Director of the HKTDC, said: “This year’s twin jewellery shows bring together some 4,000 exhibitors from over 40 countries and regions, with nearly 70% coming

FlexTrade Integrates CME Group’s FX Spot+ and EBS Market Offerings for Enhanced FX Trading9.2.2026 11:30:00 CET | Press release

The initiative will see FlexTrade FX clients seamlessly access CME Group’s primary FX markets within FlexFX. FlexTrade Systems(@FlexTrade), a global leader in multi-asset execution and order management systems, today announced an integration with CME Group’s EBS Market central limit order book (CLOB) and its FX Spot+ platform.The move is designed to diversify and deepen the sources of actionable liquidity available to FlexTrade’s FlexFX users through an integration into CME Group's substantial liquidity pools for spots via FX Spot+. Providing firm, anonymous liquidity and no last-look pricing, EBS Market is a venue for both large market participants in search of FX liquidity in an all-to-all CLOB, and for market-making banks hedging FX risk. FX Spot+ further enhances spot liquidity with Futures liquidity from CME Group. This partnership is integral in helping firms further expand FX liquidity and take advantage of global opportunity. Mutual clients of FlexTrade and CME Group can integr

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye